Table 1:
Main characteristics of the reported cases of immune-related Pneumocystis jiroveci pneumonia during immunosuppression for immune-related adverse events
| Cases | Age (years)/sex | Diagnosis | First-line treatment | Second-/third-line treatment | Immune-related adverse events | Opportunistic infection | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
| Schwarz M et al., 2019 | 79/male | NSCLC | Carboplatin-gemcitabine | Nivolumab | Pneumonitis treated by steroids | PJP | Piperacillin-tazobactam trimethoprim/sulfamethoxazole steroids | Death |
| Schwarz M et al., 2019 | 53/male | NSCLC | Cisplatin- vinorelbine followed by a right upper lobectomy | Nivolumab combined with radiotherapy | Pneumonitis treated by steroids | PJP CMV | Trimethoprim/sulfamethoxazole, steroids, broad-spectrum antibiotics, ganciclovir | Death |
| Arriola E et al., 2015 | 69/female | Melanoma | Surgical resection and lymphadenectomy | Dacarbazine and then ipilimumab | Colitis treated by steroids and infliximab | PJP | Trimethoprim/sulfamethoxazole | Recovery |
| Arriola E et al., 2015 | 63/female | Melanoma | Wide local excision and axillary block dissection | Ipilimumab | Colitis and capillary leak syndrome treated by steroids | PJP | Trimethoprim/sulfamethoxazole | Recovery |
| Slevin F et al., 2016 | 52/female | Melanoma | Vemurafenib | Ipilimumab | Ileitis and pancolitis treated by high- dose corticosteroids and infliximab | PJP | Piperacillin-tazobactam clarithromycin trimethoprim/sulfamethoxazole steroids | Recovery |
PJP: Pneumocystis jiroveci pneumonia, CMV: Cytomegalovirus, NSCLC: Non-small cell lung cancer